Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forma Therapeutics has signed a research collaboration and license option agreement with Janssen Biotech to discover, develop and commercialize novel small molecule drug candidates that target tumor metabolism mechanisms.
Subscribe to our email newsletter
As per the alliance, Forma will be responsible for the discovery and development of drugs against a range of tumor metabolism targets and will be entitled to receive project and milestone funding.
The company is said to receive up to $700m if development, regulatory and commercialization milestones are achieved for the drug candidates launched during the course of the agreement.
Furthermore, Forma is also eligible for royalties on revenues from commercialized products as a result of the collaboration and can co-develop and maintain North American commercial rights to one program of Janssen’s selection.
Forma CEO Steven Tregay said the alliance with Janssen would strengthen their drug discovery portfolio besides providing an opportunity to maintain North American rights.